Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 10/20 | 0.46 |
| ▸ | CA1 | P00915 | 9/20 | 0.46 |
| ▸ | CA9 | Q16790 | 9/20 | 0.46 |
| ▸ | CA12 | O43570 | 8/20 | 0.46 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10897393 | 1.00 | CYP3A4 (0.61) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL16357603 | 1.00 | CYP3A4 (0.61) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL10897931 | 1.00 | CYP3A4 (0.61) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL17287183 | 1.00 | CYP3A4 (0.61) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL18332762 | 0.94 | CYP3A4 (0.55) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24238614 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24806634 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL13785420 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL24824205 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB | |
| SCHEMBL21730994 | 0.93 | CYP3A4 (0.59) | CYP3A4MAPTCYP2C9CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052134-B1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-16 | — | — | US | disclosed |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-11 | — | — | US | disclosed |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2018-04-26 | — | — | US | disclosed |
| EP-2949665-B1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| EP-3280450-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2018-02-14 | — | — | EP | disclosed |
| US-9889205-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-13 | — | — | US | disclosed |
| US-9884125-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016164288-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2016-09-01 | — | — | US | disclosed |
| US-9427475-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME CORP. (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2949665-A1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-02 | — | — | EP | disclosed |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME LLC | 2015-04-16 | — | — | US | disclosed |
| US-4565863-A | ANTITUMOR AGENTS, SKIN DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1986-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | NPPA, NPR1, NPR3 | CYP3A4 3731/4885MAPT 4224/4885CYP2C9 2744/4885 |
| US-20180110863-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | CYP3A4 1438/4885MAPT 1804/4885CYP2C9 3134/4885 |
| US-20150105317-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | CYP3A4 1382/4885MAPT 1857/4885CYP2C9 3078/4885 |
| US-20160251407-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | CYP3A4 1801/4885MAPT 2065/4885CYP2C9 3492/4885 |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | CYP3A4 3731/4885MAPT 4224/4885CYP2C9 2744/4885 |
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | CYP3A4 3731/4885MAPT 4224/4885CYP2C9 2744/4885 |
| US-20160303244-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, INSR, IRS1 | CYP3A4 1382/4885MAPT 1857/4885CYP2C9 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.